Related references
Note: Only part of the references are listed.Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly: An Endocrine Society Clinical Practice Guideline
Laurence Katznelson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
A. Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
EXPERT CONSENSUS DOCUMENT A consensus on the medical treatment of acromegaly
Andrea Giustina et al.
NATURE REVIEWS ENDOCRINOLOGY (2014)
Failure of Current Laboratory Protocols to Detect Lot-to-Lot Reagent Differences: Findings and Possible Solutions
Alicia Algeciras-Schimnich et al.
CLINICAL CHEMISTRY (2013)
Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism
Akira Shimatsu et al.
ENDOCRINE JOURNAL (2013)
Effects of Lanreotide Autogel on Growth Hormone, Insulinlike Growth Factor 1, and Tumor Size in Acromegaly: A 1-Year Prospective Multicenter Study
Roberto Attanasio et al.
Endocrine Practice (2013)
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 Update
Laurence Katznelson et al.
Endocrine Practice (2013)
A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy
Anand K. Annamalai et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Novel pathway for somatostatin analogs in patients with acromegaly
Monica R. Gadelha et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2013)
AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression
Leandro Kasuki et al.
ENDOCRINE-RELATED CANCER (2012)
Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
Yasemin Tutuncu et al.
PITUITARY (2012)
Consensus Statement on the Standardization and Evaluation of Growth Hormone and Insulin-like Growth Factor Assays
David R. Clemmons
CLINICAL CHEMISTRY (2011)
Harmonization of growth hormone measurements with different immunoassays by data adjustment
Anne Mueller et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2011)
Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure
Sven M. Carlsen et al.
CLINICAL ENDOCRINOLOGY (2011)
Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly
Z. Karaca et al.
CLINICAL ENDOCRINOLOGY (2011)
Resistance to Somatostatin Analogs in Acromegaly
Annamaria Colao et al.
ENDOCRINE REVIEWS (2011)
Efficacy and Acceptability of Lanreotide Autogel® 120 mg at Different Dose Intervals in Patients with Acromegaly Previously Treated with Octreotide LAR
J. Schopohl et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2011)
The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly
T. R. Bandgar et al.
JOURNAL OF POSTGRADUATE MEDICINE (2010)
Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly
Roberto Salvatori et al.
PITUITARY (2010)
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide AutogelA® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
Shlomo Melmed et al.
PITUITARY (2010)
Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study
Annamaria Colao et al.
CLINICAL ENDOCRINOLOGY (2009)
Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly
Annamaria Colao et al.
CLINICAL ENDOCRINOLOGY (2009)
Investigation into the Efficacy and Safety of Octreotide LAR in Japanese Patients with Acromegaly: Shizuoka Study
Yutaka Oki et al.
ENDOCRINE JOURNAL (2009)
Guidelines for Acromegaly Management: An Update
S. Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly
G. Lombardi et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2009)
Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy
E. Ghigo et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2009)
Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population
Alexander Krebs et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2008)
Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide
N. Karavitaki et al.
CLINICAL ENDOCRINOLOGY (2008)
Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly
Philippe Chanson et al.
CLINICAL ENDOCRINOLOGY (2008)
Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register
S. Petersenn et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
A 12-month randomized crossover study on the effects of Lanreotide Autogel and Octreotide long-acting repeatable on GH and IGF-I in patients with acromegaly
Magdalene Andries et al.
CLINICAL ENDOCRINOLOGY (2008)
Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly
Annamaria Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Efficacy of a slow-release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR):: an open, multicentre longitudinal study
C. L. Ronchi et al.
CLINICAL ENDOCRINOLOGY (2007)
Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Raquel S. Jallad et al.
CLINICAL ENDOCRINOLOGY (2007)
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
Moises Mercado et al.
CLINICAL ENDOCRINOLOGY (2007)
Efficacy of lanreotide Autogel® administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg:: a phase III trial
T. Lucas et al.
CLINICAL ENDOCRINOLOGY (2006)
Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage
R Cozzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly
A Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution
RS Jallad et al.
CLINICAL ENDOCRINOLOGY (2005)
Long-acting somatostatin analog therapy of acromegaly: A meta- analysis
PU Freda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs
P Petrossians et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Efficacy of Sandostatin® LAR® (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy
J Ayuk et al.
CLINICAL ENDOCRINOLOGY (2004)
Efficacy and tolerability of lanreotide autogel therapy in acromegalic patients previously treated with octreotide LAR
O Alexopoulou et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel®
P Caron et al.
CLINICAL ENDOCRINOLOGY (2004)
Current concepts in the biochemical assessment of the patient with acromegaly
PU Freda
GROWTH HORMONE & IGF RESEARCH (2003)
Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: Predictive value of short-term results?
R Cozzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Use of the oral glucose tolerance test to define remission in acromegaly
H Vierhapper et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2003)
Share Paper
